Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pancrelipase is a purified enzyme mixture derived from porcine pancreatic glands, containing **lipase, protease, and amylase**. It is used as **pancreatic enzyme replacement therapy** (PERT) to aid digestion in individuals with exocrine pancreatic insufficiency (EPI), such as that due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions. Mechanistically, pancrelipase works by supplementing the body's digestive enzymes, catalyzing the breakdown of fats (via lipase), proteins (via protease), and carbohydrates (via amylase) in the small intestine, thereby improving nutrient absorption, nutritional status, and gastrointestinal symptoms[1][2][3][5][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pancrelipase (Janssen Pharmaceutical).